tailieunhanh - Báo cáo y học: "impact of oral melatonin on the electroretinogram cone respons"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Wertheim cung cấp cho các bạn kiến thức về ngành y đề tài: impact of oral melatonin on the electroretinogram cone response. | Journal of Circadian Rhythms BioMed Central Research Impact of oral melatonin on the electroretinogram cone response Anne-Marie Gagné1 Konstantin V Danilenko2 Serge G Rosolen3 4 and Marc Hébert 1 Open Access Address 1Centre de Recherche Université Laval Robert-Giffard Faculty of Medicine Université Laval Québec Canada institute of Internal Medicine Siberian Branch of the Russian Academy of Medical Sciences Novosibirsk Russia 3Centre de Recherche - Institut de la Vision UMR S968 INSERM-UPMC Paris 6 Paris France and 4Clinique Vétérinaire Voltaire Asnières France Email Anne-Marie Gagné - Konstantin V Danilenko - kvdani@ Serge G Rosolen - Marc Hébert - Corresponding author Published 19 November 2009 Received 31 July 2009 Accepted 19 November 2009 Journal of Circadian Rhythms 2009 7 14 doi 1740-3391-7-14 This article is available from http content 7 1 14 2009 Gagné et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background In the eye melatonin plays a role in promoting light sensitivity at night and modulating many aspects of circadian retinal physiology. It is also an inhibitor of retinal dopamine which is a promoter of day vision through the cone system. Consequently it is possible that oral melatonin an inhibitor of retinal dopamine taken to alleviate circadian disorders may affect cone functioning. Our aim was to assess the impact of melatonin on the cone response of the human retina using electroretinography ERG . Methods Twelve healthy participants aged between 18 to 52 years old were submitted to a placebo-controlled double-blind crossover and counterbalanced-order design. The .